India All Set To Launch Its First Nasal Covid Vaccine

34
Credit: Daniel Schludi/Unsplash

According to Bharat Biotech’s chairman and MD Krishna Ella, the intranasal COVID-19 vaccine would be made available on January 26, as reported by News On Air.

One of a kind

“Our nasal vaccine will be officially launched on January 26, on Republic Day,” conveyed MD Krishna Ella at the ‘Face-to-Face with New Frontiers in Science’ segment of the IISF, which was held at the Maulana Azad National Institute of Technology (MANIT).

In a conversation with the kids at the India International Science Festival (IISF) in Bhopal, Krishna Ella also mentioned the likelihood of the February 2023 release of Lumpi-ProVacInd, a Made-in-India vaccine for the lumpy skin condition that affects cattle.

The first-of-its-kind intranasal vaccine will cost Rs 325 per shot for government purchases and Rs 800 per shot for private vaccination facilities, according to a December 2022 announcement from Bharat Biotech.

Painless and affordable

Nasal Vaccine for cost-effectiveness in low & middle-income countries.

“We have achieved the goals we set for ourselves during this pandemic. We have developed COVAXIN and iNCOVACC, two COVID vaccines from two different platforms, with two different delivery systems. The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics,” Dr Krishna Ella had remarked earlier.

As a needleless vaccination, iNCOVACC has the dual advantages of speeding up the development of variant-specific vaccines and facilitating simple nasal administration, which enables bulk immunisation to guard against worrying new variants. Furthermore, according to Dr Arora, this vaccination will aid in the fight against not only Covid but also all respiratory viruses and illnesses.

The recombinant adenoviral vector construct for iNCOVACC was created in collaboration with Washington University in St. Louis, which also tested its efficacy in preclinical research. Clinical trials in phases I, II, and III evaluated the nasal vaccination candidate successfully. In low- and middle-income nations, the nasal delivery technique has been developed for effectiveness and cost-efficiency.


Did you subscribe to our newsletter?

It’s free! Click here to subscribe!

Source: News On Air

LEAVE A REPLY

This site uses Akismet to reduce spam. Learn how your comment data is processed.